PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.

Abstract Preclinical in vitro and in vivo studies suggest that statins could exhibit anticancer properties in ovarian cancer. Similar effects have also been reported in observational studies but their results remain inconsistent and could be impaired by methodological limitations. This study aimed to investigate whether statin use is associated with improved survival in ovarian cancer patients at the Belgian population-level.
PMID
Related Publications

Statin use and mortality among ovarian cancer patients: A population-based cohort study.

Statin use and mortality of patients with prostate cancer: a meta-analysis.

Statin use after colorectal cancer diagnosis and survival: a population-based cohort study.

Statin use and survival from lung cancer: a population-based cohort study.

Statin use and breast cancer survival: a nationwide cohort study in Scotland.

Authors

Mayor MeshTerms
Keywords
Journal Title plos one
Publication Year Start




PMID- 29261726
OWN - NLM
STAT- In-Process
LR  - 20171224
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 12
DP  - 2017
TI  - Statin use is associated with improved survival in ovarian cancer: A
      retrospective population-based study.
PG  - e0189233
LID - 10.1371/journal.pone.0189233 [doi]
AB  - BACKGROUND: Preclinical in vitro and in vivo studies suggest that statins could
      exhibit anticancer properties in ovarian cancer. Similar effects have also been
      reported in observational studies but their results remain inconsistent and could
      be impaired by methodological limitations. This study aimed to investigate
      whether statin use is associated with improved survival in ovarian cancer
      patients at the Belgian population-level. METHODS: All patients with invasive
      epithelial ovarian cancer diagnosed between 2004 and 2012 were identified from
      the Belgian Cancer Registry. Vital statuses were obtained from the Crossroads
      Bank for Social Security and ovarian cancer-specific deaths were identified from 
      death certificates provided by regional administrations. Information on cancer
      treatments and statin use were retrieved from health insurance databases. Statin 
      use was modelled as a time-varying covariate in Cox regression models to
      calculate adjusted hazards ratios (HR) and 95% confidence intervals (95%CI) for
      the association between postdiagnostic exposure to statins and overall- or
      ovarian cancer-specific mortality within three years after diagnosis. Adjustments
      were made for age at diagnosis, year of diagnosis, comorbidities, cancer stage,
      and cancer treatments. RESULTS: A total of 5,416 patients with epithelial ovarian
      cancer met the inclusion criteria. Of these 1,255 (23%) had at least one statin
      prescription within three years after diagnosis. Postdiagnostic use of statins
      was associated with a reduced risk of overall mortality (adjusted HR = 0.81,
      95%CI:0.72-0.90, p<0.001). In analyses by statin type, this association was only 
      significant for simvastatin (adjusted HR = 0.86, 95%CI:0.74-0.99, p = 0.05) or
      rosuvastatin (adjusted HR = 0.71, 95%CI:0.55-0.92, p = 0.01). In subgroup
      analyses by statin prediagnostic use, the protective association for
      postdiagnostic statin use was only observed in patients who were also using
      statins before diagnosis (adjusted HR = 0.73, 95%CI:0.64-0.83, p<0.001). Similar 
      results were observed for ovarian cancer-specific mortality. CONCLUSION: In this 
      large nation-wide cohort of ovarian cancer patients postdiagnostic use of statins
      was associated with improved survival.
FAU - Couttenier, Alexandra
AU  - Couttenier A
AUID- ORCID: http://orcid.org/0000-0003-3713-2624
AD  - Pole d'Epidemiologie et Biostatistique, Institut de Recherche Experimentale et
      Clinique, Universite catholique de Louvain, Brussels, Belgium.
FAU - Lacroix, Olivia
AU  - Lacroix O
AD  - Pole d'Epidemiologie et Biostatistique, Institut de Recherche Experimentale et
      Clinique, Universite catholique de Louvain, Brussels, Belgium.
FAU - Vaes, Evelien
AU  - Vaes E
AD  - Research Department, Belgian Cancer Registry, Brussels, Belgium.
FAU - Cardwell, Chris R
AU  - Cardwell CR
AD  - Centre for Public Health, Queen's University Belfast, Belfast, Northern Ireland.
FAU - De Schutter, Harlinde
AU  - De Schutter H
AD  - Research Department, Belgian Cancer Registry, Brussels, Belgium.
FAU - Robert, Annie
AU  - Robert A
AD  - Pole d'Epidemiologie et Biostatistique, Institut de Recherche Experimentale et
      Clinique, Universite catholique de Louvain, Brussels, Belgium.
LA  - eng
PT  - Journal Article
DEP - 20171219
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
PMC - PMC5736195
EDAT- 2017/12/21 06:00
MHDA- 2017/12/21 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/07/18 00:00 [received]
PHST- 2017/11/21 00:00 [accepted]
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2017/12/21 06:00 [medline]
AID - 10.1371/journal.pone.0189233 [doi]
AID - PONE-D-17-26789 [pii]
PST - epublish
SO  - PLoS One. 2017 Dec 19;12(12):e0189233. doi: 10.1371/journal.pone.0189233.
      eCollection 2017.